Nasdaq

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

Insulet Corporation PODD recently presented new Omnipod 5 Automated Insulin Delivery System (Omnipod 5) study outcomes for children with type 1 diabetes, aged 2 through 5.9 years, at the American ...
Morningstar

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet’s groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from ...
Monthly Prescribing Reference

Omnipod 5 Tubeless Automated Insulin Delivery System Cleared for Younger Kids

The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...
Business Wire

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
The American Journal of Managed Care

Omnipod 5 May Improve Psychosocial Outcomes for Patients With T1D, Study Suggests

Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...
Nasdaq

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...